Mesothelial cells facilitate cancer stem‑like properties in spheroids of ovarian cancer cells

Shishido,Akemi; Mori,Seiji; Yokoyama,Yuhki; Hamada,Yoshinosuke; Minami,Kazumasa; Qian,Yamin; Wang,Jiaqi; Hirose,Haruka; Wu,Xin; Kawaguchi,Naomasa; Nagumo,Sachiko; Matsuura,Nariaki; Yamamoto,Hirofumi

doi:10.3892/or.2018.6605

Mesothelial cells facilitate cancer stem‑like properties in spheroids of ovarian cancer cells

Authors:
- Akemi Shishido
- Seiji Mori
- Yuhki Yokoyama
- Yoshinosuke Hamada
- Kazumasa Minami
- Yamin Qian
- Jiaqi Wang
- Haruka Hirose
- Xin Wu
- Naomasa Kawaguchi
- Sachiko Nagumo
- Nariaki Matsuura
- Hirofumi Yamamoto
View Affiliations

Affiliations: Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan, Department of Medical Technology, Faculty of Health Sciences,Morinomiya University of Medical Sciences, Osaka City, Osaka 559‑8611, Japan, Department of Medical Physics and Engineering, Division of Health Sciences, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan
Published online on: July 27, 2018 https://doi.org/10.3892/or.2018.6605
Pages: 2105-2114

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is characterized by widespread peritoneal dissemination with ascites. Spheroids observed in the ascites of ovarian cancer patients are a mixture of cancer cells and mesothelial cells. In the present study, we evaluated whether mesothelial cells exfoliated from the peritoneum facilitate tumor spheroid formation and give rise to cancer stem‑like properties in ovarian cancer cells. Spheroids from the CAOV3 and A2780 ovarian cancer cell lines grew much larger in co‑culture with mesothelial cells than in monoculture under 3D conditions. The spheroids in co‑culture displayed high Ki‑67 expression in the peripheral zone and low expression in the central zone area. The expression of CD133 emerged in the inner portion of spheroids at later time‑points (96 and 168 h), indicating that cancer cells expanded to the inner spheroid and acquired stem cell‑properties. The mRNA levels of cancer stem cell markers Dclk‑1, CD44 and Bmi‑1 significantly increased in co‑cultured CAOV3 and mesothelial cells compared to CAOV3 cells alone. Furthermore, the mesothelial cells promoted the tumorigenesis and growth of the CAOV3 cells in a mouse xenograft model compared to cancer cells alone. In conclusion, mesothelial cells promoted spheroid formation by ovarian cancer cells and facilitated cancer stem‑like properties.

View Figures

View References

1	Ozols RF: Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol. 33 2 Suppl 6:S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI
2	Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD, et al: Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One. 9:e849412014. View Article : Google Scholar : PubMed/NCBI
3	Foster R, Buckanovich RJ and Rueda BR: Ovarian cancer stem cells: Working towards the root of stemness. Cancer Lett. 338:147–157. 2013. View Article : Google Scholar : PubMed/NCBI
4	Shield K, Ackland ML, Ahmed N and Rice GE: Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 113:143–148. 2009. View Article : Google Scholar : PubMed/NCBI
5	Burleson KM, Boente MP, Pambuccian SE and Skubitz AP: Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 4:62006. View Article : Google Scholar : PubMed/NCBI
6	Shen-Gunther J and Mannel RS: Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 87:77–83. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ayantunde AA and Parsons SL: Predictors of poor prognosis in patients with malignant ascites: A prospective study. Clin Med Diagnostics. 2:1–6. 2012. View Article : Google Scholar
8	Mackey JR and Venner PM: Malignant ascites: Demographics, therapeutic efficacy and predictors of survival. Can J Oncol. 6:474–480. 1996.PubMed/NCBI
9	Mills GB, May C, Hill M, Campbell S, Shaw P and Marks A: Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest. 86:851–855. 1990. View Article : Google Scholar : PubMed/NCBI
10	Mutsaers SE: Mesothelial cells: Their structure, function and role in serosal repair. Respirology. 7:171–191. 2002. View Article : Google Scholar : PubMed/NCBI
11	Lengyel E: Ovarian cancer development and metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
12	Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr and Skubitz AP: Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 93:170–181. 2004. View Article : Google Scholar : PubMed/NCBI
13	Strobel T and Cannistra SA: Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol. 73:362–367. 1999. View Article : Google Scholar : PubMed/NCBI
14	Mikuła-Pietrasik J, Sosińska P and Książek K: Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of α5β1 integrins and hyaluronic acid. Gynecol Oncol. 134:624–630. 2014. View Article : Google Scholar : PubMed/NCBI
15	Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y and Ottensmeier C: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 53:3830–3838. 1993.PubMed/NCBI
16	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
17	Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A and Vallera DA: Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. 130:579–587. 2013. View Article : Google Scholar : PubMed/NCBI
18	Akedo H, Shinkai K, Mukai M, Mori Y, Tateishi R, Tanaka K, Yamamoto R and Morishita T: Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: A model for tumor invasion. Cancer Res. 46:2416–2422. 1986.PubMed/NCBI
19	Stylianou E, Jenner LA, Davies M, Coles GA and Williams JD: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int. 37:1563–1570. 1990. View Article : Google Scholar : PubMed/NCBI
20	Doglioni C, Dei Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR and Viale G: Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 20:1037–1046. 1996. View Article : Google Scholar : PubMed/NCBI
21	Ma L, Lai D, Liu T, Cheng W and Guo L: Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin. 42:593–602. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, et al: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 31:161–169. 2007. View Article : Google Scholar : PubMed/NCBI
23	Domcke S, Sinha R, Levine DA, Sander C and Schultz N: Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 4:21262013. View Article : Google Scholar : PubMed/NCBI
24	Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE and Drapkin R: Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecol Oncol. 139:97–103. 2015. View Article : Google Scholar : PubMed/NCBI
25	Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, et al: Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 8:e721622013. View Article : Google Scholar : PubMed/NCBI
26	McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR and Buckanovich RJ: Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest. 121:3206–3219. 2011. View Article : Google Scholar : PubMed/NCBI
27	Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D and Kunz-Schughart LA: CD133 as a biomarker for putative cancer stem cells in solid tumours: Limitations, problems and challenges. J Pathol. 229:355–378. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ajani JA, Song S, Hochster HS and Steinberg IB: Cancer stem cells: The promise and the potential. Semin Oncol. 42 Suppl 1:S3–S17. 2015. View Article : Google Scholar : PubMed/NCBI
29	Motegi H, Kamoshima Y, Terasaka S, Kobayashi H and Houkin K: Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells. Neuropathology. 34:378–385. 2014.PubMed/NCBI
30	Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M and Ohashi K: Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma - their prognostic significance. Pathol Int. 62:792–801. 2012. View Article : Google Scholar : PubMed/NCBI
31	Yano S, Tazawa H, Hashimoto Y, Shirakawa Y, Kuroda S, Nishizaki M, Kishimoto H, Uno F, Nagasaka T, Urata Y, et al: A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases. Clin Cancer Res. 19:6495–6505. 2013. View Article : Google Scholar : PubMed/NCBI
32	Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM, Yang T and Liu W: CD133 expression in osteosarcoma and derivation of CD133⁺ cells. Mol Med Rep. 7:577–584. 2013. View Article : Google Scholar : PubMed/NCBI
33	Sangiorgi E and Capecchi MR: Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet. 40:915–920. 2008. View Article : Google Scholar : PubMed/NCBI
34	Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, et al: The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell. 149:146–158. 2012. View Article : Google Scholar : PubMed/NCBI
35	Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ and Clevers H: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 449:1003–1007. 2007. View Article : Google Scholar : PubMed/NCBI
36	Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, et al: Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet. 45:98–103. 2013. View Article : Google Scholar : PubMed/NCBI
37	Ahmed N, Riley C, Rice G and Quinn M: Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis. 22:391–402. 2005. View Article : Google Scholar : PubMed/NCBI
38	Shield K, Riley C, Quinn MA, Rice GE, Ackland ML and Ahmed N: Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 6:112007. View Article : Google Scholar : PubMed/NCBI
39	Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, et al: Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 68:2329–2339. 2008. View Article : Google Scholar : PubMed/NCBI